- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07697248
LRG GIST Patient Registry
8 juli 2026 bijgewerkt door: The Life Raft Group
Life Raft Group GIST Registry Protocol
The Life Raft Group (LRG) Patient Registry is a structured database that collects comprehensive information about individuals diagnosed with GIST.
The purpose of this registry is to facilitate research, improve understanding of the disease, track patient outcomes, and ultimately enhance patient care.
Studie Overzicht
Toestand
Werving
Gedetailleerde beschrijving
An organization called the Life Raft Group (LRG) wants to find out more about a cancer called Gastrointestinal Stromal Tumors (GIST) as well as other cancers that may or may not be related to GIST.
To collect this information, LRG has created a research registry.
A registry is a place where medical information, family history and other related information from patients is collected and stored for medical research.
The purpose of the Life Raft Group GIST registry is to collect and store medical information and other information from individuals with the same disease or other cancers that share commonalities such as molecular targets, treatments, or other factors.
Information from patients in this registry will be used for medical research to better understand GIST and these other diseases.
Scientists studying GIST and these other diseases need more accurate, real-world information to understand how these diseases affect people.
People with GIST and other related or unrelated diseases are being asked if they would like to participate in the Life Raft Group registry.
The Life Raft Group GIST registry is also linked to a tissue bank, which is a place that stores tumor tissue, blood or other samples from patients.
Participants may also be asked to provide samples to the tissue bank.
Participants would need to read and sign a separate consent form about the tissue bank.
Participants do not have to take part in any other Life Raft Group activities, including the tissue bank and online forums, to take part in this registry.
Studietype
Observationeel
Inschrijving (Geschat)
5000
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Patient Registry Department
- Telefoonnummer: 973-837-9092
- E-mail: patientregistrydepartment@liferaftgroup.org
Studie Locaties
-
-
New Jersey
-
Wayne, New Jersey, Verenigde Staten, 07470
- Werving
- The Life Raft Group
-
Contact:
- Telefoonnummer: 973-837-9092
- E-mail: patientregistrydepartment@liferaftgroup.org
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Bemonsteringsmethode
Niet-waarschijnlijkheidssteekproef
Studie Bevolking
Gastrointestinal Stromal Tumor diagnosis
Beschrijving
Inclusion Criteria:
- Gastrointestinal Stromal Tumor diagnosis
- Provide written and informed consent
Exclusion Criteria:
-
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall survival
Tijdsspanne: From the date of registry enrollment until death from any cause, assessed through follow-up for up to 25 years.
|
Time from registry enrollment until death from any cause.
|
From the date of registry enrollment until death from any cause, assessed through follow-up for up to 25 years.
|
|
Progression Free Survival
Tijdsspanne: From the date of registry enrollment until the first documented disease progression or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
Time from registry enrollment until documented disease progression or death, whichever occurs first.
|
From the date of registry enrollment until the first documented disease progression or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
|
Recurrence Free Survival
Tijdsspanne: From the date of complete surgical resection until the first documented recurrence of GIST or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
Time from registry enrollment (or from complete surgical resection, if that is the clinically relevant starting point) until the first documented recurrence of GIST or death from any cause, whichever occurs first.
|
From the date of complete surgical resection until the first documented recurrence of GIST or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
|
Disease Free Survival
Tijdsspanne: From the date of complete surgical resection until the first documented recurrence of GIST or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
Disease-free survival is defined as the time from complete surgical resection of localized GIST until the first documented recurrence of GIST or death from any cause, whichever occurs first.
|
From the date of complete surgical resection until the first documented recurrence of GIST or death from any cause, whichever occurs first, assessed through follow-up for up to 25 years.
|
|
Time of Medication
Tijdsspanne: From the date of treatment initiation until permanent discontinuation of the medication for any reason, assessed through follow-up for up to 25 years.
|
Duration of treatment with a specific systemic therapy (e.g., imatinib, sunitinib, regorafenib, ripretinib), measured from treatment initiation until permanent discontinuation for any reason, including disease progression, toxicity, patient preference, or death.
|
From the date of treatment initiation until permanent discontinuation of the medication for any reason, assessed through follow-up for up to 25 years.
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 april 2013
Primaire voltooiing (Geschat)
31 december 2099
Studie voltooiing (Geschat)
31 december 2099
Studieregistratiedata
Eerst ingediend
1 juli 2026
Eerst ingediend dat voldeed aan de QC-criteria
8 juli 2026
Eerst geplaatst (Werkelijk)
13 juli 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
13 juli 2026
Laatste update ingediend die voldeed aan QC-criteria
8 juli 2026
Laatst geverifieerd
1 juli 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- LRG2013PR112
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .